SMYD3 and hepatocellular carcinoma: In particular, SMYD3 methylates the MAP3K2 kinase, thereby promoting ERK1/2 phosphoactivation [3], and its inactivation has a protective effect in chemically induced CRC and HCC carcinogenesis [4].